William Blair research analyst Matt Phipps was quoted in this CNBC outlook story covering how healthcare stocks will perform in 2023.
“Several companies that had provided strong clinical data were able to raise funds [in 2022],” Phipps said.
Equity Research
Matt Phipps Quoted in CNBC
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news
Our Latest News
MDxHealth SA: Initiation of Research Coverage
William Blair initiated research coverage of MDxHealth SA (MDXH $2.86), a commercial-stage diagnostics company providing actionable molecular diagnostic information to personalize diagnosis and treatment of prostrate cancer and other urologic diseases.
Read moreEconomics Weekly: Commercial Real Estate Another Bump in the Road?
In this Economics Weekly, we thought it worth having a look at the current situation in commercial real estate.
Read moreIntuitive Surgical, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Intuitive Surgical, Inc. (ISRG $246.68), which offers an ecosystem of minimally invasive surgical products and services that are founded on its da Vinci robotic system.
Read more